Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05025605
PHASE1

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Sponsor: BioXcel Therapeutics Inc

View on ClinicalTrials.gov

Summary

This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

Official title: A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Key Details

Gender

All

Age Range

10 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2021-08-27

Completion Date

2026-12-31

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

DRUG

BXCL501 80 Micrograms

Sublingual film containing 80 Micrograms BXCL501

DRUG

Placebo Film

Matching Sublingual Placebo film

DRUG

BXCL501 120 Micrograms

Sublingual film containing 120 Micrograms BXCL501

DRUG

BXCL501 60 Micrograms

Sublingual film containing 60 Micrograms BXCL501 Europe Only

Locations (5)

BioXcel Clinical Research Site

Anaheim, California, United States

Bioxcel Clinical Research Site

Hialeah, Florida, United States

BioXcel Clinical Research Site

Atlanta, Georgia, United States

Bioxcel Clinical Research Site

Decatur, Georgia, United States

BioXcel Clinical Research Site

DeSoto, Texas, United States